18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease

[1]  Philip M Robson,et al.  Quantitative carotid PET/MR imaging: clinical evaluation of MR-Attenuation correction versus CT-Attenuation correction in (18)F-FDG PET/MR emission data and comparison to PET/CT. , 2015, American journal of nuclear medicine and molecular imaging.

[2]  Gerald Antoch,et al.  Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  A. S. Brandt,et al.  Diffusion-weighted MRI findings of treated and untreated retroperitoneal fibrosis. , 2014, Diagnostic and interventional radiology.

[4]  M. Forsting,et al.  Correlation of Standardized Uptake Value and Apparent Diffusion Coefficient in Integrated Whole-Body PET/MRI of Primary and Recurrent Cervical Cancer , 2014, PloS one.

[5]  Habib Zaidi,et al.  Detection and quantification of focal uptake in head and neck tumours: 18F-FDG PET/MR versus PET/CT , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  M. Forsting,et al.  Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. , 2013, European journal of radiology.

[7]  Blanca Paño Brufau,et al.  Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.

[8]  A. S. Brandt,et al.  An Aid to Decision-Making in Therapy of Retroperitoneal Fibrosis: Dynamic Enhancement Analysis of Gadolinium MRI , 2013, Journal of clinical medicine research.

[9]  Uwe Pietrzyk,et al.  Does PET/MR in human brain imaging provide optimal co-registration? A critical reflection , 2012, Magnetic Resonance Materials in Physics, Biology and Medicine.

[10]  M. Halaç,et al.  FDG PET/CT in monitoring treatment of retroperitoneal fibrosis. , 2012, Revista espanola de medicina nuclear e imagen molecular.

[11]  O. Ratib,et al.  18F-FDG PET/CT and Contrast-Enhanced CT in a One-Stop Diagnostic Procedure: A Better Strategy for Management of Patients Suffering From Retroperitoneal Fibrosis? , 2012, Clinical nuclear medicine.

[12]  G. Treglia,et al.  [18F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience , 2012, Japanese Journal of Radiology.

[13]  P. Messa,et al.  The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. , 2012, European journal of nuclear medicine and molecular imaging.

[14]  A. S. Brandt,et al.  MR evaluation of retroperitoneal fibrosis. , 2011, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[15]  G. Piccoli,et al.  Positron emission tomography as a tool for the 'tailored' management of retroperitoneal fibrosis: a nephro-urological experience. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  T. Hendriksz,et al.  (18)F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. , 2010, European journal of internal medicine.

[17]  A. Matsuzaki,et al.  18F-Fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of idiopathic retroperitoneal fibrosis associated with mediastinal fibrosis , 2010, Annals of nuclear medicine.

[18]  M. Magrey,et al.  Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? , 2009, Arthritis and rheumatism.

[19]  M. Uder,et al.  Ormond’s Disease or Secondary Retroperitoneal Fibrosis? An Overview of Retroperitoneal Fibrosis , 2009, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[20]  Nassir Navab,et al.  Tissue Classification as a Potential Approach for Attenuation Correction in Whole-Body PET/MRI: Evaluation with PET/CT Data , 2009, Journal of Nuclear Medicine.

[21]  J. Peterson,et al.  Hypermetabolic activity in patients with active retroperitoneal fibrosis on F-18 FDG PET: report of three cases , 2007, Annals of nuclear medicine.

[22]  金子 文成,et al.  長時間歩行時の下肢筋の活動状態:[ 18 F]fluorodeoxyglucoseを用いたPositron Emission Tomographyによる検討 , 2008 .

[23]  T. Geoghegan,et al.  Imaging and intervention of retroperitoneal fibrosis. , 2007, Australasian radiology.

[24]  A. S. Brandt,et al.  ["Retroperitoneal Fibrosis" (RPF) Urologic Cooperation and Research Project]. , 2007, Der Urologe. Ausg. A.

[25]  N. Salkind.  Encyclopedia of Measurement and Statistics , 2006 .

[26]  A. Vaglio,et al.  Retroperitoneal fibrosis , 2006, The Lancet.

[27]  Thomas Beyer,et al.  Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  A. Vaglio,et al.  Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent "scar" ? A study using 18F-fluorodeoxyglucose positron emission tomography. , 2005, Clinical and experimental rheumatology.

[29]  G. Boustead,et al.  Role of gadolinium-enhanced magnetic resonance imaging in retroperitoneal fibrosis. , 2002, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[30]  T. Fernández-Villa,et al.  Retroperitoneal fibrosis: typical and atypical manifestations. , 2000, The British journal of radiology.

[31]  Russo Em,et al.  Typical and atypical manifestations of celiac disease , 1979 .

[32]  T. Asch,et al.  Retroperitoneal fibrosis. An anatomic and radiologic review with a report of four new cases and an explanation of pathogenesis. , 1960, Radiology.